KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.72
+0.23 (+1.39%)
At close: 4:00PM EDT

16.72 0.00 (0.00%)
After hours: 4:15PM EDT

Stock chart is not supported by your current browser
Previous Close16.49
Open16.74
Bid14.81 x 800
Ask19.00 x 800
Day's Range16.50 - 16.97
52 Week Range6.35 - 21.42
Volume297,531
Avg. Volume762,506
Market Cap934.676M
Beta (5Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

    SAN DIEGO, June 11, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy. A copy of the presentation is available on Kura's website at www.kuraoncology.com/pipeline/publications.

  • GlobeNewswire

    Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020. “We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    SAN DIEGO, May 08, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healthcare Conference 2020. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.

  • GlobeNewswire

    Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $125.1 million. The offering is expected to close on or about May 8, 2020, subject to customary closing conditions.

  • GlobeNewswire

    Kura Oncology Announces Commencement of Public Offering of Common Stock

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. SVB Leerink, Cowen and Credit Suisse are acting as joint bookrunning managers in the offering.

  • GlobeNewswire

    Kura Oncology Reports First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financial results and provided a corporate update. “We recently completed a strategic review of our portfolio with the goal of prioritizing programs that have the highest potential to create value,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Report First Quarter 2020 Financial Results

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of U.S. financial markets on Monday, May 4, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-516-3514 for domestic callers and 281-973-6129 for international callers and entering the conference code: 2085246.

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. “This important designation from the FDA comes just two months after tipifarnib was awarded Fast Track for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC),” said Bridget Martell, M.A., M.D., Acting Chief Medical Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

    – Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company.

  • GlobeNewswire

    Kura Oncology to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, Feb. 19, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 18, 2020 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Announces Transition of Chief Medical Officer

    – Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and.

  • GlobeNewswire

    Kura Oncology to Present at J.P. Morgan Healthcare Conference

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Thursday, January 16, 2020 at 10:00 a.m. PT / 1:00 p.m. ET, followed by a Q&A session at 10:30 a.m. PT / 1:30 p.m. ET. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

  • GlobeNewswire

    Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Officer. Ms. Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfizer in July 2019. “Kirsten is a world-class leader in building successful commercial organizations and launching precision medicines for the treatment of cancer,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC) after progression on platinum therapy. “We are very encouraged by our growing body of clinical data for tipifarnib in HRAS mutant HNSCC and believe that the FDA’s Fast Track designation puts us one step closer to delivering a precision medicine treatment for patients with this devastating disease,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

    – Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR).

  • GlobeNewswire

    Kura Oncology to Participate in Piper Jaffray Healthcare Conference

    SAN DIEGO, Nov. 26, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology to Present at Stifel Healthcare Conference

    SAN DIEGO, Nov. 12, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the.

  • GlobeNewswire

    Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting

    SAN DIEGO, Nov. 06, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of.

  • GlobeNewswire

    Kura Oncology Appoints James Basta as Chief Legal Officer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Corporate Secretary. Mr. Basta will also serve as the Company’s Chief Compliance Officer. “We are privileged to have an executive of Jim’s caliber join our senior leadership team,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire

    Kura Oncology to Report Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 30, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment.

  • GlobeNewswire

    Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today reported updated data from a Phase 2 clinical trial of its lead drug candidate, tipifarnib, that show durable anti-tumor activity as a single agent in heavily pretreated patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC). As of the October 17, 2019 data cutoff date, a total of 21 HNSCC patients with high HRAS mutant variant allele frequency1 were enrolled in this Phase 2 trial (RUN-HN), of whom 18 were evaluable for efficacy. Ten of the 18 evaluable patients achieved a confirmed partial response (PR), as defined by standard RECIST criteria, for an objective response rate (ORR) of 56% (95% CI 0.31, 0.78).